NextCure Q2 net loss $18M; cash $249.5M; trials NC318/NC410/NC762 on track

NextCure, Inc.

2022-Q2 EPS reported -$1.25

Net loss of $18.0M for Q2 2021 vs $14.5M in Q2 2020; R&D $11.9M, G&A $6.0M.
Cash, equivalents & marketable securities $249.5M as of June 30, 2021; funded into H2 2023.
NC318 Phase 2 update expected Q4 2021; dosing revised to 800 mg weekly; NSCLC cohort resumed.
NC410 initial Phase 1 data expected Q4 2021; NC762 Phase 1 started, data mid-2022.
CLIA-validated assay for S15+ patient selection available for NC318 trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.